MANKIND Mankind Pharma Q1 FY26 results (Apr–Jun 2025) and concall
Mankind Pharma reported a healthy start to FY26 with overall revenues growing 24.5% YoY, driven by strong domestic and international performance, including BSV consolidation. Despite a decline in PAT due to higher finance and depreciation costs, and gross margin compression from sales mix and inventory accruals, the company maintained its full-year guidance for EBITDA margins and is actively reducing debt. Strategic initiatives in R&D and BSV integration are progressing, with expectations for improved performance in subsequent quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 3,199 | 3,079 | 3,570 |
| EBITDA | 816 | 683 | 847 |
| Net profit | 385 | 425 | 445 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
